These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22170548)

  • 1. Immune evasion strategies of the human gamma-herpesviruses: implications for viral tumorigenesis.
    Zhang X; Dawson CW; He Z; Huang P
    J Med Virol; 2012 Feb; 84(2):272-81. PubMed ID: 22170548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis.
    Liang C; Lee JS; Jung JU
    Semin Cancer Biol; 2008 Dec; 18(6):423-36. PubMed ID: 18948197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune control of oncogenic γ-herpesviruses.
    Jung J; Münz C
    Curr Opin Virol; 2015 Oct; 14():79-86. PubMed ID: 26372881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the Macroautophagic Machinery, Cellular Differentiation, and Immune Responses by Human Oncogenic γ-Herpesviruses.
    Münz C
    Viruses; 2021 May; 13(5):. PubMed ID: 34066671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?
    Moore PS; Chang Y
    Annu Rev Microbiol; 2003; 57():609-39. PubMed ID: 14527293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells and herpesviruses: a model of lymphoproliferation.
    Barozzi P; Potenza L; Riva G; Vallerini D; Quadrelli C; Bosco R; Forghieri F; Torelli G; Luppi M
    Autoimmun Rev; 2007 Dec; 7(2):132-6. PubMed ID: 18035323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV.
    Taylor GS; Blackbourn DJ
    Cancer Lett; 2011 Jun; 305(2):263-78. PubMed ID: 21470769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is murine gammaherpesvirus-68 (MHV-68) a suitable immunotoxicological model for examining immunomodulatory drug-associated viral recrudescence?
    Aligo J; Walker M; Bugelski P; Weinstock D
    J Immunotoxicol; 2015; 12(1):1-15. PubMed ID: 24512328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for immune evasion by human tumor viruses.
    Bussey KA; Brinkmann MM
    Curr Opin Virol; 2018 Oct; 32():30-39. PubMed ID: 30241043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells.
    Nachmani D; Stern-Ginossar N; Sarid R; Mandelboim O
    Cell Host Microbe; 2009 Apr; 5(4):376-85. PubMed ID: 19380116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncogenic gamma herpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) hijack retinoic acid-inducible gene I (RIG-I) facilitating both viral and tumour immune evasion.
    Nash A; Ryan EJ
    Tumour Virus Res; 2022 Dec; 14():200246. PubMed ID: 35998812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel immune evasion mechanism of LMP-1, an EBV-primary oncogene, in nasopharyngeal carcinoma.
    Yoshizaki T
    Adv Otorhinolaryngol; 2011; 72():157-9. PubMed ID: 21865718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal Transduction Pathways Associated with KSHV-Related Tumors.
    Watanabe T; Sugimoto A; Hosokawa K; Fujimuro M
    Adv Exp Med Biol; 2018; 1045():321-355. PubMed ID: 29896674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Viruses in Carcinogenesis and Molecular Targeting: From Infection to Being a Component of the Tumor Microenvironment.
    Dzobo K
    OMICS; 2021 Jun; 25(6):358-371. PubMed ID: 34037476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reflections on Epstein-Barr virus: some recently resolved old uncertainties.
    Epstein MA
    J Infect; 2001 Aug; 43(2):111-5. PubMed ID: 11676516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.
    Cesarman E
    Cancer Lett; 2011 Jun; 305(2):163-74. PubMed ID: 21493001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune evasion by Kaposi's sarcoma-associated herpesvirus.
    Coscoy L
    Nat Rev Immunol; 2007 May; 7(5):391-401. PubMed ID: 17457345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the transforming mechanisms of Epstein-Barr virus, Kaposi's sarcoma-associated herpesvirus, and Herpesvirus saimiri.
    Damania B; Jung JU
    Adv Cancer Res; 2001; 80():51-82. PubMed ID: 11034540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular virology of Kaposi's sarcoma-associated herpesvirus.
    Moore PS; Chang Y
    Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):499-516. PubMed ID: 11313008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV-NK cells interactions and lymphoproliferative disorders.
    Kanegane H; Yachie A; Miyawaki T; Tosato G
    Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.